Pictet Asset Management’s Immunovant IMVT Stock Holding History

Pictet Asset Management’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.7M	Buy	472,381 +91,539	+24%	+$2.37M	0.01%	615
2025 Q4	$9.68M	Sell	380,842 -295,735	-44%	-$6.59M	0.01%	680
2025 Q3	$10.9M	Sell	676,577 -512,001	-43%	-$8.29M	0.01%	654
2025 Q2	$19M	Hold	1,188,578	–	–	0.02%	519
2025 Q1	$20.3M	Buy	1,188,578 +12,893	+1%	+$270K	0.02%	494
2024 Q4	$29.1M	Sell	1,175,685 -54,624	-4%	-$1.55M	0.03%	401
2024 Q3	$35.1M	Buy	1,230,309 +55,493	+5%	+$1.64M	0.04%	359
2024 Q2	$31M	Sell	1,174,816 -90,482	-7%	-$2.57M	0.04%	370
2024 Q1	$40.9M	Sell	1,265,298 -42,133	-3%	-$1.54M	0.04%	348
2023 Q4	$55.1M	Buy	1,307,431 +172,226	+15%	+$6.34M	0.06%	288
2023 Q3	$43.6M	Buy	+1,135,205	New	+$25.7M	0.05%	308

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Pictet Asset Management's IMVT Position: Q1 2026 in Review

Pictet Asset Management increased its Immunovant (IMVT) stake by 24% in Q1 2026, buying an estimated $2.37M and bringing the position to 472,381 shares worth $11.7M. The position accounts for 0.01% of the portfolio, ranked #615.

Pictet Asset Management first reported a position in IMVT in Q3 2023 and has held it in 11 quarters since. The position peaked at $55.1M in Q4 2023. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

Pictet Asset Management held 472,381 shares of Immunovant worth $11.7M as of Q1 2026.
Pictet Asset Management bought 91,539 Immunovant shares in Q1 2026, an estimated $2.37M.
Immunovant made up 0.01% of Pictet Asset Management's portfolio in Q1 2026, its #615 holding.
Pictet Asset Management first reported a position in Immunovant in Q3 2023 and has held it in 11 quarters since.
Pictet Asset Management's Immunovant position peaked at $55.1M in Q4 2023.
215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Pictet Asset Management's 13F filing for Q1 2026, filed 22 Apr 2026.